Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's fall risk could be cut in half by common memory drug

NCT ID NCT04226248

Disease control Sponsor: University of Bristol Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether rivastigmine, a drug already used for memory problems in Parkinson's, can reduce falls. 600 people with Parkinson's who had fallen in the past year took either the drug or a placebo patch for 12 months and recorded their falls. The goal was to see if the drug could help people pay better attention to their walking and prevent falls.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

600 people

The number who actually took part.

Started

Jan 2020

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of idiopathic Parkinson's disease. * Modified Hoehn and Yahr stage 1-4 disease as determined at baseline visit. * Have experienced a fall in the previous year. * Able to walk ≥10m without aids or assistance. * 18+ years of age. Exclusion Criteria: * Previous ChEi use in 12 months prior to enrolment. * Hypersensitivity to rivastigmine * Dementia diagnosed according to MDS criteria (6). * Inability to attend or comply with treatment or follow-up scheduling. * Non-English-speaking patients (cognitive tests performed in English). * Falling ≥4x per day. * Unwillingness to use an acceptable method of contraception for the duration of the trial if they are of childbearing potential. * Pregnancy and/or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • Aneurin Bevan University Health Board

    Newport, NP18 3XQ, United Kingdom

  • Barking, Havering and Redbridge University Hospitals NHS trust

    Romford, Accepted, BS8 1NU, United Kingdom

  • Barnsley Hospital NHS Foundation Trust

    Barnsley, S75 2EP, United Kingdom

  • Betsi Cadwaladr University Health Board

    Bangor, Gwynedd, LL57 2PW, United Kingdom

  • Betsi Cadwaladr University Health Board

    Wrexham, LL13 7YP, United Kingdom

  • Gateshead Health NHS Foundation Trust

    Gateshead, NE9 6SX, United Kingdom

  • Gloucestershire Hospitals NHS Foundation Trust

    Gloucester, GL1 3NN, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, W6 8RF, United Kingdom

  • Lancashire Teaching Hospitals NHS Foundation Trust

    Preston, PR2 9HT, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    Leeds, LS2 3AX, United Kingdom

  • Lothian Health Board NHS

    Edinburgh, Scotland, EH1 3EG, United Kingdom

  • Manchester University NHS Foundation Trust

    Manchester, England, M13 9WL, United Kingdom

  • NHS Forth Valley

    Larbert, Scotland, FK5 4WR, United Kingdom

  • NHS Grampian

    Aberdeen, AB15 6RE, United Kingdom

  • NHS Tayside

    Dundee, DD2 1UB, United Kingdom

  • Newcastle Hospitals NHS Foundation Trust

    Newcastle, NE7 7DN, United Kingdom

  • Norfolk and Norwich University Hospital

    Norwich, Norfolk, NR4 7UY, United Kingdom

  • North Bristol NHS Trust

    Bristol, BS10 5NB, United Kingdom

  • North Tees and Hartlepool Hospitals NHS Foundation Trust

    Stockton-on-Tees, TS19 8PE, United Kingdom

  • North West Anglia NHS Foundation Trust

    Peterborough, PE3 9GZ, United Kingdom

  • Northumbria Healthcare NHS Foundation Trust

    Newcastle, NE27 0QJ, United Kingdom

  • Oxford University Hospitals

    Oxford, OX3 9DU, United Kingdom

  • Pennine Acute Hospitals NHS Trust

    Bury, BL9 7TD, United Kingdom

  • Princess of Wales Hospital (Cwm Taf Morgannwg University Health Board)

    Bridgend, CF31 1RQ, United Kingdom

  • Royal Berkshire NHS Foundation Trust

    Reading, RG1 5AN, United Kingdom

  • Royal United Hospitals Bath NHS Foundation Trust

    Bath, Somerset, BA1 3NG, United Kingdom

  • Salford Royal NHS Foundation Trust

    Salford, MA6 8HD, United Kingdom

  • Somerset NHS Foundation Trust

    Taunton, TA1 5DA, United Kingdom

  • South Tees Hospitals NHS Foundation Trust

    Middlesbrough, TS4 3BS, United Kingdom

  • The Walton Centre NHS Foundation Trust

    Liverpool, L9 7LJ, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, WC1N 3BG, United Kingdom

  • University Hospitals Bristol and Weston NHS Foundation Trust

    Bristol, BS1 3NU, United Kingdom

  • University Hospitals Dorset NHS Foundation Trust

    Bournemouth, BH23 2JX, United Kingdom

  • University Hospitals Plymouth NHS Trust

    Plymouth, PL6 5FP, United Kingdom

  • University Hospitals of Derby and Burton NHS Foundation Trust

    Derby, DE22 3NE, United Kingdom

  • University Hospitals of Leicester NHS Foundation Trust

    Leicester, LE1 5WW, United Kingdom

  • Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust

    Wigan, WN1 2NN, United Kingdom

  • Yeovil District Hospital

    Yeovil, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.